Neurohospitalist/Inpatient Neurology
The Neurohospitalist Program at the University of Colorado maintains a strong commitment to discovery, leading and participating in a broad range of research initiatives, including clinical trials, aimed at improving diagnostic strategies, therapeutic interventions, and most importantly, patient outcomes in acute care, hospital-based neurology.
Actively Enrolling Studies
TREATMENT OF MYASTHENIA GRAVIS EXACERBATION OR CRISIS WITH EFGARTIGIMOD
Treatment of myasthenia gravis exacerbation or crisis with efgartigimod: A single arm, open label prospective cohort study.
Investigator: Andrew Wolf, MD
ClinicalTrials.gov Identifier: NCT06860633 (https://clinicaltrials.gov/study/NCT06860633)
TANRUPRUBART IN GUILLAIN-BARRE SYNDROME
A Clinical Study to Evaluate ANX005 (Tanruprubart) in Participants with Guillain-Barre Syndrome (FORWARD)
Investigator: Brian Sauer, MD, PhD
ClinicalTrials.gov Identifier: NCT07020819 (https://clinicaltrials.gov/study/NCT07020819)
TREATMENT OF INFLAMMATORY MYELITIS AND OPTIC NEURITIS WITH EARLY VERSUS RESCUE PLASMA EXCHANGE
Treatment of Inflammatory Myelitis and Optic Neuritis with Early vs Rescue Plasma Exchange (TIMELY-PLEX)
Investigator(s): Jeffery Bennett, MD, PhD; Brian Sauer, MD, PhD
ClinicalTrials.gov Identifier: NCT07100990 (https://clinicaltrials.gov/study/NCT07100990)
INEBILIZUMAB IN NMDAR ENCEPHALITIS
Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease (ExTINGUISH)
Investigator: Amanda Piquet, MD
ClinicalTrials.gov Identifier: NCT04372615 (https://clinicaltrials.gov/study/NCT04372615)
SATRALIZUMAB IN NMDAR OR LGI-1 AUTOIMMUNE ENCEPHALITIS
Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis (CIELO)
Investigator: Amanda Piquet, MD
ClinicalTrials.gov Identifier: NCT05503264 (https://clinicaltrials.gov/study/NCT05503264)